Efficacy and safety of low-dose aspirin in polycythemia vera.

By R. Landolfi, R. Marchioli, J. Kutti, H. Gisslinger, G. Tognoni, C. Patrono, T. Barbui. New England Journal of Medicine, 2004

942 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/c82e1d9b9fe9ce55807441800abf35638f6661d5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. F. Cervantes
2. A. Tefferi
3. A. Pardanani
4. R. Hehlmann
5. G. Barosi
6. G. Birgegard
7. R. Silver
8. N. Kröger

Citations in the corpus

• Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. (2011, methodology): “Patients enrolled onto the Low-Dose Aspirin in Polycythemia Vera (ECLAP) study failed to show any correlation between hematocrit levels up to 50% and thrombosis.(19) Risk stratification in PMF is addressed to death from any cause.”